- Wallonia Minister of Economy and Employment Pierre-Yves Jeholet will perform opening ceremony on 9 January 2026
- New cleanroom facility allows production of one million devices per year
- Ramping up for clinical development in osteoarthritis in 2026
- Supports launch of Synoglide™ in veterinary markets worldwide
Liege, Belgium – 9 January 2026 (08:30 CET) – Allegro NV, a biomedical company developing transformative injectable, mechanically-acting devices for osteoarthritis, will officially launch production of its first microparticle hydrogel device after a ceremonial opening of its cleanroom manufacturing facility on 9 January 2026. After an investment worth multiple millions of euros, the state-of-the art facility enables annual production of a million devices per year. The production will amongst others supply partner American Regent with Synoglide™, a novel animal health device for osteoarthritis in the equine market, which has been launched recently in the US, for commercialization in veterinary markets worldwide.
“We are honored that Minister Jeholet will be with us as we celebrate this moment, in recognition of the strengths of the life sciences industry in Wallonia.” said Lucas Decuypere, Chief Executive Officer at Allegro. “It makes me incredibly proud that we are starting production of our innovative product just four years after launching Allegro. We are planning to start clinical trials in 2026, aiming to hand back mobility to the hundreds of millions of people suffering from osteoarthritis around the world.”
Wallonia Minister for Economic Affairs, Industry, the Digital Economy, Employment and Training Pierre-Yves Jeholet will perform the opening in the presence of senior representatives from public bodies and the life sciences industry in Belgium on Friday, 9 January 2026.
Horses are a strong translational model for humans in joint disease and Allegro is now fully focused on the human clinical development of its hydrogel technology with Hydrocelin. It is planning to launch a feasibility study in humans in the first half of 2026, which will be followed by a global registrational trial. Allegro last year signed an exclusive licensing deal Allegro signed with American Regent, a leading company in the U.S. specializing in injectables for human and animal health, to commercialize its technology in veterinary markets. American Regent launched the product, Synoglide™, at the annual meeting of the American Association of Equine Practitioners (AAEP) in Denver, Colorado, in December last year.
Important information
The contents of this announcement include statements that are, or may be deemed to be, “forward-looking statements”. These forward-looking statements can be identified by the use of forward-looking terminology, including the words “believes”, “estimates,” “anticipates”, “expects”, “intends”, “may”, “will”, “plans”, “continue”, “ongoing”, “potential”, “predict”, “project”, “target”, “seek” or “should”, and include statements the Company makes concerning the intended results of its strategy. By their nature, forward-looking statements involve risks and uncertainties and readers are cautioned that any such forward-looking statements are not guarantees of future performance. The company’s actual results may differ materially from those predicted by the forward-looking